论文部分内容阅读
14年来移植肾急性排异(AR)的靶位经临床和动物试验研究已明确为脉管内皮细胞和肾小管上皮细胞(TEC)。在10～15毫升尿沉渣做TEC计数是一种简便、无害且在2小时可出结果的技术,此法较移植肾活检安全、快速且可靠是其优点。从1977年10月至1978年9月尿TEC研究结果如下:(1)23例健康人都无TEC,13例移植前尿毒症仅0～5 TEC;(2)在移植后病人尿TEC数少于15为阴性,15～25为可疑,26及以上为阳性;(3)移植直后,肾如受急性肾小管坏死损伤TEC阳性时并非AR;(3)一年间共测知54次AR,其中51次在TEC阳性前3天至后2天出现临床AR;有三次AR未被TEC测知。故此TEC所诊断的AR率为94%。
Acute renal allograft rejection over 14 years has been identified by clinical and animal studies as vascular endothelial cells and tubular epithelial cells (TECs). The TEC count of 10-15 ml urine sediment is a simple, harmless, and achievable result in 2 hours, an advantage over safe, fast and reliable graft biopsy. The results of urine TEC from October 1977 to September 1978 were as follows: (1) There was no TEC in 23 healthy people and only 0 ~ 5 TEC in 13 cases before transplantation; (2) 15 was negative, 15 to 25 were suspicious, 26 and above were positive; (3) Transplanted straight after kidney injury caused by acute tubular necrosis is not AR when TEC positive; (3) A total of 54 AR measured a year, Fifty-one clinical clinical AR occurred 3 days to 2 days after TEC positive; three ARs were not detected by TEC. Therefore, TEC diagnosed AR rate was 94%.